| Filed On | Filing |
|---|---|
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition; Other Events
SAN DIEGO - (BUSINESS WIRE-October 29, 2026) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2026. |
| 14 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
SAN DIEGO - (BUSINESS WIRE- September 14, 2026) - DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the promotion of Jereme Sylvain to the role of Chief Operating Officer (COO) in addition to his duties... |
| 10 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
SAN DIEGO - (BUSINESS WIRE- September 10, 2026) - DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO - (BUSINESS WIRE-July 30, 2026) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2026. |
| 28 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 27, 2026, DexCom, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the close of business on April 1, 2026, the record date for the Annual Meeting, there were 385,872,977 shares of Dexcom... |
| 15 May 2026 |
8-K: Regulation FD Disclosure; Other Events
On May 14, 2026, DexCom, Inc. (“Dexcom”) held its 2026 Investor Day in Mesa, Arizona, discussing, among other things, information regarding Dexcom’s market opportunities, business strategy, innovation efforts, and long-term financial out... |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO - (BUSINESS WIRE-April 30, 2026) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2026. |
| 02 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On behalf of DexCom Inc. (the “Company”) and its Board of Directors (the “Board”), I want to thank you for your many years of service to the Company, during which you have demonstrated remarkable leadership and have made immeasurable con... |
| 26 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
SAN DIEGO - (BUSINESS WIRE- February 26, 2026) - DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Rick Osterloh to its Board of Directors, effective February 26, 2026. |
| 12 Feb 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO - (BUSINESS WIRE-February 12, 2026) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2025. |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO - (BUSINESS WIRE-January 7, 2026) - DexCom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, is ushering in the next era of transformative, customer-driven innovation under the leadership of President and CEO Jake L... |
| 22 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Congratulations! Dexcom (“Dexcom”, or the “Company”) is pleased to confirm your promotion to become Chief Executive Officer. The effective date of your promotion will be January 1, 2026 (“Effective Date”) (at which time your service as P... |
| 30 Oct 2025 |
8-K: Results of Operations and Financial Condition
SAN DIEGO - (BUSINESS WIRE-October 30, 2025) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2025. |
| 27 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
SAN DIEGO - (BUSINESS WIRE- October 27, 2025) - DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Euan Ashley to its Board of Directors, effective October 24, 2025. |
| 16 Sep 2025 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 30 Jul 2025 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
SAN DIEGO - (BUSINESS WIRE-July 30, 2025) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2025. |
| 13 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
SAN DIEGO--(BUSINESS WIRE)—May 13, 2025-- DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of Jake Leach to president, in addition to his current role as chief opera... |
| 09 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
1.PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, and any Parents and Subsidiaries that ex... |
| 02 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. |
| 01 May 2025 |
8-K: Results of Operations and Financial Condition; Other Events
SAN DIEGO - (BUSINESS WIRE-May 1, 2025) - DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2025. |
Loading...